Resverlogix Corp.
TSX : RVX

Resverlogix Corp.

June 05, 2006 09:20 ET

Theresa Kennedy Joins ResVerlogix Corp. as VP Corporate Communications

CALGARY, ALBERTA--(CCNMatthews - June 5, 2006) - ResVerlogix Corp. ("ResVerlogix") (TSX:RVX) announced today that Theresa Kennedy has joined the company as Vice President Corporate Communications, effective immediately. Mrs. Kennedy will provide strategic leadership and insight for the company's communication activities.

"We are very pleased with Mrs. Kennedy's appointment to the Senior Management team, she brings a solid record of working with some of the industry's top biotech companies across a number of communication disciplines," said Mr. Donald McCaffrey, President and CEO of ResVerlogix. Mr. McCaffrey added, "This appointment, as well as our recently appointed CFO position, was made in order to support the growth and operational focus of our company as we move forward in developing innovative new therapies for cardiovascular, cancer and fibrotic diseases."

Mrs. Kennedy brings more than 14 years of biotechnology experience with her most recent role was Vice President of North American Life Sciences for Hill & Knowlton Canada, a global communications firm. She was previously Executive Director for BC Biotech a provincial biotech association. In addition to these positions Mrs. Kennedy is a regular presenter at biotech conferences and meetings including most recently lecturing at Oxford University as part of the E.U. Ph.D. program for biotechnology. In May 2005, Mrs. Kennedy was recognized by BIOTECanada with an award for Contribution for Advancing the Benefits of Biotech for Canadians.

Mrs. Kennedy has her B.Sc. from the University of Calgary.

About ResVerlogix Corp.

ResVerlogix Corp. is a Canadian biotechnology company engaged in the discovery and development of biopharmaceuticals. Combining expertise with innovation, ResVerlogix's lead technology NexVas™, applies advanced medical research to develop therapies that increase ApoA-I the key protein of high density lipoprotein (HDL), the "good cholesterol," and other targets to treat cardiovascular diseases (CVD). The Company's second CVD research program ReVas™ is dedicated to developing novel compounds for acute based drug therapy via a medical device. ResVerlogix Corp. is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. ResVerlogix Corp. trades on the TSX Exchange under the symbol RVX. For further information, please visit our web site at: www.ResVerlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of ResVerlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

Contact Information

  • ResvVerlogix Corp.
    Donald J. McCaffrey
    President/CEO
    (403) 254-9252 ext. 223
    (403) 256-8495 (FAX)
    Email: don@resverlogix.com
    or
    ResVerlogix Corp.
    Kenneth Lebioda
    Vice President Business Development
    (403) 254-9252 ext. 227
    (403) 256-8495 (FAX)
    Email: ken@resverlogix.com
    Website: www.resverlogix.com